A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

ConditionSolid Tumor

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18-70

SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd

About this trial

This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.

Eligibility criteria

Qualifiers

Fully understand the study and voluntarily sign the informed consent form.

Male or female 18-70 years of age;

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or

Life expectancy ≥ 3 months.

Disqualifiers

Patients were deemed unsuitable for participating in the study by the investigator for any reasons.

Trial design

Treatments tested in this trial

ZG005 Powder for Injection
Donafenib Tosilate Tablets

Treatment groups

130 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Lead sponsor

Source ClinicalTrials.gov